In a 45-year-old man with recent upper respiratory infection presenting with lingering cough, laugh‑induced wheeze, and nasal congestion, what treatment is recommended?

Post-Viral Upper Respiratory Tract Infection with Lingering Cough

For this 45-year-old man with resolving upper respiratory infection and lingering cough with wheeze and nasal congestion, treat with a first-generation antihistamine/decongestant combination (such as brompheniramine 6 mg plus sustained-release pseudoephedrine 120 mg twice daily) along with nasal saline irrigation and consider topical intranasal corticosteroids. 1, 2, 3

Clinical Reasoning

This patient's presentation is classic for post-viral upper airway cough syndrome (UACS), previously called postnasal drip syndrome. The key diagnostic features are:

• Recent viral URI that has improved over the past week
• Persistent cough and nasal congestion as residual symptoms
• Laugh-induced wheeze (suggesting airway irritability)
• No red flags suggesting bacterial superinfection or complications

The timeline (improving symptoms with lingering cough) indicates this is not acute bacterial rhinosinusitis, which would require symptoms persisting ≥10 days without improvement or worsening after initial improvement ("double worsening") 1, 2. Since symptoms are improving, antibiotics are not indicated.

Treatment Algorithm

First-Line Therapy

1. First-Generation Antihistamine/Decongestant Combination

• This is the most evidence-based treatment for post-viral cough 4, 3
• Specific regimens proven effective:
  • Brompheniramine 6 mg + pseudoephedrine 120 mg (sustained-release) twice daily, OR
  • Dexbrompheniramine 6 mg + pseudoephedamine 120 mg twice daily
• Why first-generation? The anticholinergic properties (not just antihistamine effects) reduce secretions and cough 3
• Important: Newer non-sedating antihistamines (loratadine, terfenadine) are ineffective for post-viral cough 4, 3
• Start once daily at bedtime for 2-3 days to minimize sedation, then advance to twice daily 3

2. Nasal Saline Irrigation

• Low risk, palliative benefit for nasal congestion 1, 2
• Can use physiologic or hypertonic concentrations

3. Topical Intranasal Corticosteroids

• Modest benefit (number needed to treat = 14) 2
• Helps reduce nasal inflammation and congestion
• Safe with rare adverse effects 2

Adjunctive Therapy

For the Wheeze Component:

• The laugh-induced wheeze suggests post-viral airway hyperreactivity
• Consider short-acting bronchodilator (albuterol) as needed for wheeze 5
• If wheeze persists beyond 2 weeks, evaluate for:
  • Cough variant asthma (would show bronchial hyperresponsiveness)
  • Non-asthmatic eosinophilic bronchitis (eosinophilia without hyperresponsiveness) 5

For Symptomatic Relief:

• Analgesics (ibuprofen, acetaminophen) for any residual discomfort 2
• Oral decongestants alone may help if antihistamine/decongestant combination is contraindicated 2

Critical Pitfalls to Avoid

1. Do NOT prescribe antibiotics - This is a resolving viral illness, not bacterial rhinosinusitis 1, 2, 6

2. Do NOT use newer antihistamines - Loratadine, cetirizine, and other non-sedating antihistamines are ineffective for post-viral cough because they lack the anticholinergic properties needed 4, 3

3. Avoid topical decongestants >3-5 days - Risk of rebound congestion (rhinitis medicamentosa) 2

4. Screen for contraindications to decongestants:

• Uncontrolled hypertension
• Severe anxiety
• Glaucoma
• Benign prostatic hypertrophy with urinary symptoms 2, 3

Alternative if contraindications exist: Ipratropium bromide nasal spray may be effective 3

Expected Timeline

• Improvement should occur within days to 2 weeks of starting first-generation antihistamine/decongestant therapy 3
• Approximately 25% of patients with viral URI have persistent cough at day 14, which correlates with ongoing sinus inflammation 4
• If no improvement after 2 weeks of appropriate therapy, reassess for:
  • Alternative diagnoses (cough variant asthma, eosinophilic bronchitis, GERD)
  • Need for induced sputum analysis if available 5

What NOT to Use

Evidence shows these are ineffective or unproven for post-viral cough:

• Guaifenesin (expectorant) - no clinical efficacy data 2
• Dextromethorphan (cough suppressant) - no evidence for viral cough 2
• Antihistamines in non-atopic patients without decongestant 2
• Systemic corticosteroids - not indicated for simple post-viral cough 2

The anticholinergic effect of first-generation antihistamines combined with decongestant vasoconstriction addresses the pathophysiology of post-viral UACS by reducing secretions and mucosal inflammation 3.